Journals / Molecular Imaging and Radionuclide Therapy / 2016 / Cilt: 25 - Sayı: 3

Fokal Andiferansiye Komponentli Agresif Seyirli Papiller Tiroid Karsinomu: Olgu Sunumu

Aggressive Disease Course of Papillary Thyroid Carcinoma with Focal Undifferentiated Component: A Case Report

Pages
134–139
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Focally undifferentiated thyroid carcinoma is an expression of the extreme end of the spectrum of differentiated thyroid carcinoma

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We report an aggressive papillary thyroid carcinoma (PTC) with focal undifferentiated component in a 32-year-old female.
📊
Key Findings & Data:Within 12 months of thyroidectomy and radioiodine ablation, thyroglobulin (Tg) levels were elevated.
💡
Conclusion & Impact:Focally undifferentiated thyroid carcinoma is an expression of the extreme end of the spectrum of differentiated thyroid carcinoma
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

We report an aggressive papillary thyroid carcinoma (PTC) with focal undifferentiated component in a 32-year-old female. She had limited disease confined within the thyroid gland at diagnosis. Within 12 months of thyroidectomy and radioiodine ablation, thyroglobulin (Tg) levels were elevated. Second radioiodine ablative dose was given, however, stimulated Tg levels showed an upward trend with negative iodine scan within 12 months. An 18F fludeoxyglucose-avid solitary pulmonary nodule that was detected on positron emission tomography/computed tomography scan was resected followed by empiric radioiodine therapy. Within the next 10 months she developed multifocal bone metastases. The multifocal disease was rendered inoperable and treated with external beam radiation. The patient is on follow-up, and the Tg level continues to rise with local disease progression. In a small percentage of patients, PTC behaves as a very aggressive disease despite treatment. Focally undifferentiated thyroid carcinoma is an expression of the extreme end of the spectrum of differentiated thyroid carcinoma

Özet

Otuz iki yaşında bir kadında saptanan fokal andiferansiye komponentli agresif seyirli papiller tiroid karsinomu sunulmaktadır. Tanı anında tiroid bezi ile sınırlı hastalığı mevcuttu. Tiroidektomi ve radyoiyot ablasyondan 12 ay sonra tiroglobulin (Tg) değerleri yükselmeye başladı. İkinci radyoiyot ablasyon dozu uygulandı, ancak stimule Tg düzeyleri yükselme eğiliminde idi ve 12. ayda iyot sintingrafisi negatif idi. Pozitron emisyon tomografisi/bilgisayarlı tomografi ile 18F florodeoksiglukoz-avid soliter pulmoner nodül saptandı, rezeke edildi ve ampirik radyoiyot tedavisi uygulandı. Takip eden 10 ay içinde multifokal kemik metastazları saptandı. Multifokal hastalık inoperabl olarak değerlendirildi ve eksternal radyasyon ile tedavi edildi. Hasta halen takip altında olup Tg değeri lokal hastalık progresyonu ile birlikte yükselmeye devam etmektedir. Hastaların küçük bir bölümünde papiller tiroid karsinomu tedaviye rağmen agresif seyirli olabilir. Fokal andiferansiye tiroid karsinomu diferansiye tiroid karsinom spektrumunun en aşırı ucunu temsil etmektedir

🔖

Cite This Article

RİAZ, S., BASHİR, H., HASSAN, A., MUSHTAQ, S., JAMSHED, A., MURTAZA, A. (2016). Fokal Andiferansiye Komponentli Agresif Seyirli Papiller Tiroid Karsinomu: Olgu Sunumu. Molecular Imaging and Radionuclide Therapy, Cilt: 25 - Sayı: 3, 134–139. https://ajindex.com/articles/295134

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Nambiar A, Pv S, Susheelan V, Kuriakose MA. The concepts in poorly differentiated carcinoma of the thyroid: a review article. J Surg Oncol 2011;103:818-821.
  2. Eichhorn W, Tabler H, Lippold R, Lochmann M, Schreckenberger M, Bartenstein P. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid 2003;13:949-958. LiVolsi VA. Papillary thyroid carcinoma: an update. Mod Pathol 2011;24 Suppl 2:S1-9. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-241.
  3. Abboud B, Tannoury J. Surgical treatment of papillary thyroid carcinoma. J Med Liban 2011;59:206-212.
  4. Baloch Z, LiVolsi VA, Tondon R. Aggressive variants of follicular cell derived thyroid carcinoma; the so called 'real thyroid carcinomas'. J Clin Pathol 2013;66:733-743.
  5. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck 2010;32:829-836.
  6. Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, Ito K, Ito K. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011;21:1183- 1189. Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 2012;36:1247-1254.
  7. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989;63:908-911.
  8. Perri F, Lorenzo GD, Scarpati GD, Buonerba C. Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol 2011;2:150-157.
  9. Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011;21:25-30.
  10. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH. Completely resected anaplastic thyroid carcinoma combined wi